New nasal COVID vaccine could replace needles
NCT ID NCT07416539
First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times
Summary
This early-stage trial is testing a new nasal spray vaccine called COV2 against COVID-19. Twenty healthy adults who have already had at least two COVID-19 shots will receive two doses of one of two formulations. The study aims to check if the vaccine is safe and whether it boosts the body's immune defenses against the Omicron BA.5 variant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- COV2 vaccine (nasal spray, adenoviral vector-based)
- What this could lead to
- If successful, this could lead to a needle-free COVID-19 vaccine that may be easier to administer and could boost immunity against variants.
- What could go wrong
- This is a very early Phase 1 trial with only 20 participants, so safety and immune response are still unproven. The vaccine may not work as hoped or could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kuopio University Hospital, ENT policlinic
Kuopio, Northern Savonia, 70210, Finland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?